The weight-loss drug craze

As Americans prepare to vote in the November 3 midterm elections, the FT’s chief economics commentator Martin Wolf asks what the result will mean for Donald Trump, the future of US democracy and America's place in the world. In the third of a six-part series, Martin speaks to pol ...  Show more

Alphabet’s share price fell just over 12 percent on Thursday, and UK startup Nscale is banking on a troubled US data centre project to underpin its planned $35bn IPO. Plus, we look at what’s next for the ECB now that its president Christine Lagarde announced she’s stepping down.M ...  Show more

Eli Lilly and Novo Nordisk can’t keep up with demand for their weight loss medications. In this Viewsroom podcast, Breakingviews columnists discuss the hype among celebrities, the different approaches to prescribing them in the US and Europe, and how they can reshape the world. V ...  Show more

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ...  Show more

What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ...  Show more